https://anthelos.com/wp-content/uploads/2021/01/output-onlinepngtools-7.png

NewsImmediate Action: Our Response to COVID-19

12/30/2020

Within the first few weeks after Anthelos foundation, our team of specialists validated a real-time Reverse Transcriptase PCR (QPCR) assay for the specific detection of the SARS-CoV-2 virus using saliva, sputum and nasal swabs. We used our know-how to establish the Inf-Cov2QuantTM Influenza A/B + SARS-CoV-2 Quantification Kit (ICQ-100), which is a multiplex molecular in vitro diagnostic kit, with CE and IVD authentication, capable of detecting and differentiating the presence of Influenza A and B viruses and novel coronavirus (SARS-CoV-2) RNA from the same upper or lower respiratory tract sample (such as nasopharyngeal, oropharyngeal, and nasal swabs, sputum, lower respiratory, bronchoalveolar lavage, and nasopharyngeal lavage fluids).